HealthEquity Reports Strong Q2 Results but Shares Drop Amid Disappointing Guidance
Despite reporting better-than-expected second-quarter results, HealthEquity (NASDAQ: HQY) experienced a significant stock decline this week. The healthcare financial services company reported non-GAAP earnings of $1.24 per share and revenue of $350.7 million for the quarter ending July 31, both exceeding Wall Street forecasts. However, investors were dissatisfied with management's updated guidance. HealthEquity only slightly raised its full-year sales target to between $1.411 billion and $1.421 billion—just above previous estimates—and reiterated adjusted EPS guidance of $4.66–$4.73, which fell short of expectations for a more robust outlook. The stock closed the week down 8.6%, with intraday losses reaching as high as 12%. Despite this pullback, shares remain up about 8% year to date.
